Figure 2
Figure 2
Cumulative incidence of all-cause death among patients by antibiotic type over 10 days (IPTW).
HR = hazard ratio; IPTW = inverse probability treatment weights.
In this issue
Related Articles
Cited By...
- Antibiotic utilisation and the impact of antimicrobial resistance action plan on prescribing among older adults in New Zealand between 2005 and 2019
- Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
- BET 1: What is the incidence of cardiac arrhythmia in adult patients with acute infection prescribed fluoroquinolones?
- Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea
- Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases
- Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides
- Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities
- Does macrolide use confer risk of out-of-hospital cardiac arrest compared with penicillin V? A Danish national case-crossover and case-time-control study
- Indias antibiotic combinations thwart efforts to curb drug resistance, say researchers
- Use of azithromycin and risk of ventricular arrhythmia
- Macrolide antibiotics and the risk of ventricular arrhythmia in older adults
- Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes
- Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain
- In This Issue: Building Blocks for Improving Practice